Skip to Content

Ellen Relkin

Partner and Practice Group Chair at Weitz & Luxenberg

Ms. Relkin, whose practice focuses on medical device and pharmaceutical product liability, as well as toxic tort matters, has represented thousands of plaintiffs injured by defective medical products with a recent focus on the generation of failed metal-on-metal and modular hip implants.

 

She serves in leadership capacities appointed by courts as the Co-Lead Counsel of the In Re: DePuy ASR Multi-District Litigation (MDL) and the Lead and Liaison Counsel for the New Jersey In Re: Stryker Rejuvenate & ABG II Modular Hip Implant Litigation as well as a member of the Plaintiff Steering Committee in the In Re: Xarelto Product Liability Litigation and the Executive Committee of In Re: Invokana (Canagliflozin) Products Liability Litigation.

 

She had served on the court-appointed Executive Committee of the MDL involving the birth control patch Ortho Evra, and as the Plaintiffs’ Liaison counsel in the New Jersey consolidated litigation involving the oral contraceptives Yaz, Yasmin and Ocella, as well as on the Court Appointed Plainitffs’ Steering Committee of the In Re: Biomet Hip Implant Litigation.

 

In April 2006, she was part of the trial team that secured a $13.5 million verdict in McDarby v. Merckin a failure-to-warn case involving the medication Vioxx and the risk for heart attack, and she successfully defended the compensatory damage verdict on appeal.

 

Education

  • J.D., Rutgers University Law School, 1984
  • B.A., cum laude in history, with distinction, Cornell University, 1980
  • Clerkship, The Honorable Sylvia Pressler, then Presiding Judge of New Jersey Superior Court, Appellate Division 1984 – 1985

 

Notable Cases

  • 13.5 Million (2006; W&L secures verdict in N.J. Vioxx trial)
  • 1 Billion (2014; Global Resolution Reached in Lawsuits over Stryker Rejuvenate and ABG II Failed Hips)